Yohimbine attenuates the delayed lethality induced in mice by amitraz, a formamidine pesticide

Evaluation of developmental toxicity of amitraz in Sprague-Dawley rats

This study investigated the potential adverse effects of amitraz on the initiation and maintenance of pregnancy in Sprague-Dawley rats as well as its effects on embryo-fetal development after maternal exposure during the entire pregnancy period. Amitraz was administered to pregnant rats by gavage from days 1 to 19 of gestation at dose levels of 0, 3, 10, and 30 mg/kg/day. All dams underwent a caesarean section on day 20 of gestation and their fetuses were examined for any external, visceral, and skeletal abnormalities. At 30 mg/kg, maternal toxicity manifested as an increase in the incidence of abnormal clinical signs and a lower body weight gain and food intake. Developmental toxicity included an increase in the fetal death rate, a decrease in the litter size, and a reduction in the fetal body weight. In addition, there was an increase in the incidence of fetal external, visceral, and skeletal abnormalities. At 10 mg/kg, maternal toxicity observed included a decrease in the body weight gain and a decrease in food intake. In addition, minimal developmental toxicity, including a decrease in the fetal body weight, an increase in the visceral and skeletal aberrations, and a delay in fetal ossification. There were no signs of either maternal toxicity or developmental toxicity at 3 mg/kg. These results show that amitraz administered during the entire pregnancy period in rats is embryotoxic and teratogenic at the maternally toxic dose (i.e., 30 mg/kg/day) and is minimally embryotoxic at a minimally maternally toxic dose (i.e., 10 mg/kg/day). Under these experimental conditions, the no-observed-adverse-effect level of amitraz for both dams and embryo-fetal development is estimated to be 3 mg/kg/day.

Rat strain and stock comparisons using a functional observational battery: baseline values and effects of amitraz

A functional observational battery (FOB) was utilized to assess the effects of 3-day exposure to the formamidine pesticide amitraz in outbred Sprague-Dawley-derived and inbred Fischer-344-derived (F344) rats (both from Charles River Laboratories) and in outbred Long-Evans rats obtained from two commercial suppliers (Charles River Breeding Laboratories and Blue Spruce Farms). Significant strain and stock differences were obtained in baseline values for one-third of the FOB measures. In most cases, F344 rats were different from the others. Characteristic signs of amitraz exposure consisting of increased excitability, hyper-reactivity, and physiological and autonomic changes were evident in all treated rats. These effects increased with repeated dosing, and many were still present 6 days after dosing. On individual measures, there were differences between the strains and stocks in terms of sensitivity and time course of amitraz effects. In general, Blue Spruce Long-Evans rats displayed more effects of amitraz and F344 rats recovered more quickly than others. Although Sprague-Dawley rats showed the least effect overall, they displayed the largest increases in the sensorimotor responses to stimuli. These data indicate that although some behavioral and physiological parameters showed strain and supplier differences, in both baseline values and the effects of amitraz, conclusions concerning its neurotoxic potential in a screening context would be similar.

The effects of yohimbine and four other antagonists on amitraz-induced depression of shuttle avoidance responses in dogs

The ability of five antagonists to prevent the central nervous system's depressant effects of amitraz in dogs was evaluated using a shuttle avoidance paradigm. All drugs were injected iv into six male dogs trained to avoid a 1-mA shock by jumping over a hurdle within 10 sec of the start of a tone. Dogs were given an antagonist or saline followed in 5 min by 3 mg/kg amitraz dissolved in dimethyl sulfoxide (DMSO) or DMSO alone. After pretreatment with saline, amitraz decreased significantly the means number of avoidance responses and increased significantly the means latencies of avoidance responses. After pretreatment with the alpha 2-adrenoreceptor antagonist yohimbine (0.1 mg/kg), amitraz no longer decreased the means number of avoidance responses or lengthened the means latencies of avoidance responses. The nonselective alpha-adrenoreceptor antagonist tolazoline (3.3 mg/kg) prevented amitraz-induced increases in means latencies, but did not prevent the decreases in the means number of avoidances. The alpha 1-adrenoreceptor antagonist prazosin (1 mg/kg), the muscarinic receptor antagonist atropine (0.04 mg/kg), and the opioid receptor antagonist naloxone (1 mg/kg) did not prevent either of amitraz's effects. The data suggest that the amitraz-induced suppression of avoidance responding is mediated by alpha 2-adrenoreceptors rather than by alpha 1-adrenergic, muscarinic, or opioid receptors.

Interactions of neurotoxicants with neurotransmitter systems

Many neurotoxic compounds have been shown to interfere with neurotransmission both in vitro and following acute and chronic administration. Various parameters of neurotransmission can be directly affected by neurotoxicants; these include the enzyme(s) synthesizing a neurotransmitter, the release and uptake processes, the enzyme(s) which metabolize the neurotransmitter, the receptors, and post-synaptic events associated with receptor activation. Some neurotoxicants can interfere with neurotransmission indirectly, by interacting for example with energy metabolism, sodium channels or ATPases. Furthermore, measured alterations of any parameter of neurotransmission can be the result of neuronal death, due to a cytotoxic effect of the neurotoxicants. Chemicals which have been shown to alter neurotransmission include solvents (e.g. carbon disulfide), metals and organometals (e.g. lead, mercury, trimethyltin) and pesticides (e.g. organophosphates, pyrethroids, organochlorines, formamidines). An example of the various alterations in neurotransmitter parameters, which can occur following acute or chronic administration, is represented by the organophosphates. Organophosphorus insecticides owe their acute toxicity to inhibition of acetylcholinesterase and accumulation of acetylcholine at cholinergic receptors. Chronic exposure to these compounds results in the development of tolerance to their toxicity which is associated with a decrease in the density of muscarinic and nicotinic receptors in both the central and peripheral nervous system. Other examples of the interactions of neurotoxicants with neurotransmitters are also described.

Alpha 2-adrenoceptors as a target for formamidine pesticides: in vitro and in vivo studies in mice

While the toxicity in insects of formamidines such as chlordimeform (CDM), its demethylated metabolite DCDM, and amitraz (AMZ) appears to involve activation of an octopamine-sensitive adenylate cyclase, their mechanism of action in mammals remains elusive. There is increasing evidence, however, that alpha 2-adrenoceptors might mediate certain effects of CDM, DCDM, and AMZ. In the present study, we investigated whether formamidines can interact directly with adrenoceptors in mouse forebrain both in vitro and after in vivo administration. Formamidines were potent inhibitors of the binding of [3H]clonidine to alpha 2-adrenoceptors with IC50's of 13 microM, 29 nM, and 130 nM for CDM, DCDM, and AMZ, respectively. Binding of [3H]yohimbine was inhibited with similar potencies. All compounds also inhibited with equal (CDM) or lower potency the binding of [3H]spiperone to dopamine D2 receptors and were weak inhibitors or inactive toward alpha 1- and beta-adrenoceptors, cholinergic muscarinic, GABAA, opiate mu, benzodiazepine, and histamine 1 receptors. Administration of formamidines to mice caused a dose-dependent decrease of [3H]clonidine binding. [3H]Clonidine binding returned to control values within 5 hr following administration of CDM and DCDM, but was still significantly decreased up to 48 hr after AMZ. Among different brain regions, [3H]clonidine binding was decreased to a larger extent in cerebral cortex, hippocampus, and midbrain. In vitro and ex vivo kinetic binding studies indicated that the effect of formamidines on alpha 2-adrenoceptors was due to a decrease in affinity and not to an alteration of the density of [3H]clonidine binding sites. The results of these biochemical studies support the hypothesis that alpha 2-adrenoceptors represent an important target for formamidine neurotoxicity in mammals.

The bradycardic and mydriatic effects of chlordimeform and its demethylated analogs in the rat: antagonism by idazoxan but not by prazosin

Pupillary and cardiac responses to i.v. injections of chlordimeform (CDM, 0.3-10 mg/kg), a formamidine insecticide, and its metabolites demethylchlordimeform (DCDM, 0.03-1 mg/kg) and didemethylchlordimeform (DDCDM, 0.1-3 mg/kg) were studied in rats anesthetized with pentobarbital. Both CDM and DCDM induced a dose-dependent mydriasis and bradycardia and DCDM was 10 times more potent than CDM in causing these effects. In contrast, DDCDM did not induce a mydriasis or bradycardia. The alpha 2-adrenoreceptor antagonist, idazoxan (0.2 mg/kg, i.v.) abolished or reduced CDM- and DCDM-induced mydriasis and bradycardia, whereas the alpha 1-adrenoreceptor antagonist, prazosin (1.5 mg/kg, i.v.) did not change these effects of CDM and DCDM. SKF 525-A (50 mg/kg, i.p.), an inhibitor of enzymatic demethylation, administered 10 min before the first dose of CDM, failed to reduce the effects of CDM. The results suggested: 1) the mydriatic and bradycardic effects of CDM and DCDM are mediated by alpha 2-adrenoreceptors, 2) the monodemethylation of CDM increases its alpha 2-adrenoreceptor agonistic activities, but the didemethylation of CDM abolishes these activities, and 3) CDM can exert alpha 2-adrenoreceptor agonistic activities without undergoing a demethylation process.

Effect of yohimbine on amitraz-induced CNS depression and bradycardia in dogs

Yohimbine was studied to examine its effectiveness in preventing central nervous system(CNS) depression and bradycardia induced by amitraz (N'-(2,4-dimethylphenyl)-N-[(2,4-dimethylphenyl-imino)-methyl]-N-methyl- methanimide). In control open-field activity experiments, the dogs showed high numbers of grid-line crossings in the first 5 min (exploratory phase), and subsequently low numbers of grid-line crossings (nonexploratory phase). An iv injection of amitraz (1 mg/kg) abolished both the exploratory and nonexploratory phases and caused bradycardia. Yohimbine alone caused a trend to increase the open-field activity in the nonexploratory phase. In addition, yohimbine prevented the bradycardia and suppression of open-field activity induced by amitraz. The results suggest that yohimbine has a potential to be used as an antidote for amitraz overdose.